Myeloma Registry Platform (MYRIAM)

Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.

Eligibility

Inclusion Criteria:

* MM requiring systemic (first-, second- or third-line) treatment (closed for first-line / second-line recruitment)
* Age ≥ 18 years
* Written informed consent

  * Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment
  * Patients not participating in the PRO satellite: signing of informed consent not later than four weeks after start of respective treatment, and not more than eight weeks before the start of respective systemic treatment
* Sufficient German language skills for participation in the PRO satellite

Exclusion Criteria:

* No systemic therapy for myeloma
* Patients already enrolled in studies that prohibit any participation in other studies

Conditions2

Browse More Trials